American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and …
K Cusi, S Isaacs, D Barb, R Basu, S Caprio… - Endocrine Practice, 2022 - Elsevier
Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
B Xu, S Li, B Kang, J Zhou - Cardiovascular diabetology, 2022 - Springer
Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …
disease and affects nearly a quarter of the global population. The objective of this work was …
Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures–2019 update: cosponsored …
JI Mechanick, C Apovian, S Brethauer… - Surgery for Obesity and …, 2020 - Elsevier
Objective The development of these updated clinical practice guidelines (CPG) was
commissioned by the American Association of Clinical Endocrinologists, The Obesity …
commissioned by the American Association of Clinical Endocrinologists, The Obesity …
[HTML][HTML] Dapagliflozin and cardiovascular outcomes in type 2 diabetes
Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …
Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not …
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …
morbidity and mortality in patients with established disease. Secular trends in the …
Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes
CF Deacon - Frontiers in endocrinology, 2019 - frontiersin.org
Dipeptidyl peptidase-4 (DPP-4), also known as the T-cell antigen CD26, is a multi-functional
protein which, besides its catalytic activity, also functions as a binding protein and a ligand …
protein which, besides its catalytic activity, also functions as a binding protein and a ligand …
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
O Mosenzon, TM Blicher, S Rosenlund… - The lancet Diabetes & …, 2019 - thelancet.com
Background Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor
agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly …
agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly …
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020Table. No title available.
R Chawla, SV Madhu, BM Makkar… - Indian journal of …, 2020 - journals.lww.com
Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2
Diabetes Mellitus 2020Table. No title available.
Diabetes Mellitus 2020Table. No title available.
Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors
AJ Scheen - Circulation research, 2018 - Am Heart Assoc
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …